GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » T2 Biosystems Inc (LTS:0A57) » Definitions » Institutional Ownership

T2 Biosystems (LTS:0A57) Institutional Ownership : 0.93% (As of Apr. 24, 2025)


View and export this data going back to 2020. Start your Free Trial

What is T2 Biosystems Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, T2 Biosystems's institutional ownership is 0.93%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, T2 Biosystems's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, T2 Biosystems's Float Percentage Of Total Shares Outstanding is 61.88%.


T2 Biosystems Institutional Ownership Historical Data

The historical data trend for T2 Biosystems's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

T2 Biosystems Institutional Ownership Chart

T2 Biosystems Historical Data

The historical data trend for T2 Biosystems can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 1.51 2.24 3.48 2.76 2.73 2.43 2.71 2.00 1.44 0.93

T2 Biosystems Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


T2 Biosystems Business Description

Traded in Other Exchanges
Address
101 Hartwell Avenue, Lexington, MA, USA, 02421
T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.

T2 Biosystems Headlines

No Headlines